

## Contents

### Part I Introduction – Epigenetics 1

- 1 **Epigenetics: Moving Forward** 3  
*Lucia Altucci*
- 1.1 Why This Enormously Increased Interest? 4
- 1.2 Looking Forward to New Avenues of Epigenetics 5
- Acknowledgments 7
- References 7

### Part II General Aspects/Methodologies 11

- 2 **Structural Biology of Epigenetic Targets: Exploiting Complexity** 13  
*Martin Marek, Tajith B. Shaik, and Christophe Romier*
- 2.1 Introduction 13
- 2.2 DNA Methylases: The DNMT3A–DNMT3L–H3 and DNMT1–USP7 Complexes 14
- 2.3 Histone Arginine Methyltransferases: The PRMT5–MEP50 Complex 16
- 2.4 Histone Lysine Methyltransferases: The MLL3–RBBP5–ASH2L and the PRC2 Complexes 17
- 2.5 Histone Lysine Ubiquitinylases: The PRC1 Complex 21
- 2.6 Histone Lysine Deubiquitinylases: The SAGA Deubiquitination Module 22
- 2.7 Histone Acetyltransferases: The MSL1 and NUA4 Complexes 24
- 2.8 Histone Deacetylases: HDAC1–MTA1 and HDAC3–SMRT Complexes and HDAC6 26
- 2.9 Histone Variants and Histone Chaperones: A Complex and Modular Interplay 28

2.10	ATP-Dependent Remodelers: CHD1, ISWI, SNF2, and the SNF2-Nucleosome Complex	31
2.11	Epigenetic Readers: Histone Crotonylation Readers and the 53BP1-Nucleosome (H2AK15Ub–H4K20me2) Complex	35
2.12	Conclusions	37
	Acknowledgments	38
	References	38
<b>3</b>	<b>Computer-based Lead Identification for Epigenetic Targets</b>	<b>45</b>
	<i>Chiara Luise, Tino Heimburg, Berin Karaman, Dina Robaa, and Wolfgang Sippl</i>	
3.1	Introduction	45
3.2	Computer-based Methods in Drug Discovery	46
3.2.1	Pharmacophore-based Methods	46
3.2.2	QSAR	47
3.2.3	Docking	47
3.2.4	Virtual Screening	48
3.2.5	Binding Free Energy Calculation	49
3.3	Histone Deacetylases	49
3.3.1	Zinc-Dependent HDACs	49
3.3.2	Sirtuins	54
3.4	Histone Methyltransferases	58
3.5	Histone Demethylases	61
3.5.1	LSD1 (KDM1A)	62
3.5.2	Jumonji Histone Demethylases	64
3.6	Summary	66
	Acknowledgments	66
	References	67
<b>4</b>	<b>Mass Spectrometry and Chemical Biology in Epigenetics Drug Discovery</b>	<b>79</b>
	<i>Christian Feller, David Weigt, and Carsten Hopf</i>	
4.1	Introduction: Mass Spectrometry Technology Used in Epigenetic Drug Discovery	79
4.1.1	Mass Spectrometry Workflows for the Analysis of Proteins	80
4.1.2	Mass Spectrometry Imaging	83
4.2	Target Identification and Selectivity Profiling: Chemoproteomics	85
4.2.1	Histone Deacetylase and Acetyltransferase Chemoproteomics	87
4.2.2	Bromodomain Chemoproteomics	88
4.2.3	Demethylase Chemoproteomics	88
4.2.4	Methyltransferase Chemoproteomics	89
4.3	Characterization of Epigenetic Drug Target Complexes and Reader Complexes Contributing to Drug's Mode of Action	89
4.3.1	Immunoaffinity Purification of Native Protein Complexes	89
4.3.2	Immunoaffinity Purification with Antibodies Against Epitope Tags	90

4.3.3	Affinity Enrichment Using Histone Tail Peptides as Bait	91
4.4	Elucidation of a Drug's Mode of Action: Analysis of Histone Posttranslational Modifications by MS-Based Proteomics	91
4.4.1	Histone Modification MS Workflows	92
4.4.2	Application of Histone MS Workflows to Characterize Epigenetic Drugs	95
4.5	Challenges and New Trends	97
4.5.1	Challenges and Trends in MS Analysis of Histone PTMs	97
4.5.2	High-Throughput Mass Spectrometry-Based Compound Profiling in Epigenetic Drug Discovery	98
4.5.3	Mass Spectrometry Imaging of Drug Action	98
	Acknowledgments	99
	References	99
<b>5</b>	<b>Peptide Microarrays for Epigenetic Targets</b>	<b>107</b>
	<i>Alexandra Schutkowski, Diana Kalbas, Ulf Reimer, and Mike Schutkowski</i>	
5.1	Introduction	107
5.2	Applications of Peptide Microarrays for Epigenetic Targets	110
5.2.1	Profiling of Substrate Specificities of Histone Code Writers	110
5.2.2	Profiling of Substrate Specificities of Histone Code Erasers	114
5.2.3	Profiling of Binding Specificities of PTM-specific Antibodies and Histone Code Readers	117
5.2.3.1	Profiling of Specificities of PTM-specific Antibodies	118
5.2.3.2	Profiling of Binding Specificities of Histone Code Readers	119
5.2.4	Peptide Microarray-based Identification of Upstream Kinases and Phosphorylation Sites for Epigenetic Targets	121
5.3	Conclusion and Outlook	124
	Acknowledgment	124
	References	124
<b>6</b>	<b>Chemical Probes</b>	<b>133</b>
	<i>Amy Donner, Heather King, Paul E. Brennan, Moses Moustakim, and William J. Zuercher</i>	
6.1	Chemical Probes Are Privileged Reagents for Biological Research	133
6.1.1	Best Practices for the Generation and Selection of Chemical Probes	134
6.1.2	Best Practices for Application of Chemical Probes	136
6.1.3	Cellular Target Engagement	137
6.1.3.1	Fluorescence Recovery After Photobleaching (FRAP)	138
6.1.3.2	Affinity Bead-Based Proteomics	138
6.1.3.3	Cellular Thermal Shift Assay (CETSA)	139
6.1.3.4	Bioluminescence Resonance Energy Transfer	139
6.2	Epigenetic Chemical Probes	141
6.2.1	Histone Acetylation and Bromodomain Chemical Probes	141
6.2.1.1	CBP/p300 Bromodomain Chemical Probes	144
6.2.1.2	Future Applications of Bromodomain Chemical Probes	147

- 6.3 Summary 147
- References 148

### Part III Epigenetic Target Classes 153

- 7 Inhibitors of the Zinc-Dependent Histone Deacetylases 155**  
*Helle M. E. Kristensen, Andreas S. Madsen, and Christian A. Olsen*
  - 7.1 Introduction: Histone Deacetylases 155
  - 7.2 Histone Deacetylase Inhibitors 158
    - 7.2.1 Types of Inhibitors 158
    - 7.2.2 HDAC Inhibitors in Clinical Use and Development 160
    - 7.3 Targeting of HDAC Subclasses 169
      - 7.3.1 Class I Inhibitors 169
        - 7.3.1.1 HDAC1–3 Inhibitors 170
        - 7.3.1.2 HDAC Inhibitors Targeting HDAC8 173
      - 7.3.2 Class IIa Inhibitors 174
      - 7.3.3 Class IIb 176
    - 7.4 Perspectives 177
    - References 179
- 8 Sirtuins as Drug Targets 185**  
*Clemens Zwerger, Dante Rotili, Sergio Valente, and Antonello Mai*
  - 8.1 Introduction 185
  - 8.2 Biological Functions of Sirtuins in Physiology and Pathology 185
  - 8.3 SIRT Modulators 188
    - 8.3.1 SIRT Inhibitors 188
      - 8.3.1.1 Small Molecules 188
      - 8.3.1.2 Peptides and Pseudopeptides 191
    - 8.3.2 SIRT Activators 191
  - 8.4 Summary and Conclusions 192
  - References 193
- 9 Selective Small-Molecule Inhibitors of Protein Methyltransferases 201**  
*H. Ümit Kaniskan and Jian Jin*
  - 9.1 Introduction 201
  - 9.2 Protein Methylation 201
  - 9.3 Lysine Methyltransferases (PKMTs) 202
  - 9.4 Inhibitors of PKMTs 202
    - 9.4.1 Inhibitors of H3K9 Methyltransferases 202
    - 9.4.2 Inhibitors of H3K27 Methyltransferases 204
    - 9.4.3 Inhibitors of H3K4 and H3K36 Methyltransferases 206
    - 9.4.4 Inhibitors of H4K20 Methyltransferases 208
    - 9.4.5 Inhibitors of H3K79 Methyltransferases 210
  - 9.5 Protein Arginine Methyltransferases (PRMTs) 211

9.5.1	Inhibitors of PRMT1	211
9.5.2	Inhibitors of PRMT3	212
9.5.3	Inhibitors of CARM1	213
9.5.4	Inhibitors of PRMT5	214
9.5.5	Inhibitors of PRMT6	214
9.6	Concluding Remarks	215
	References	215
<b>10</b>	<b>LSD (Lysine-Specific Demethylase): A Decade-Long Trip from Discovery to Clinical Trials</b>	<b>221</b>
	<i>Adam Lee, M. Teresa Borrello, and A. Ganesan</i>	
10.1	Introduction	221
10.2	LSDs: Discovery and Mechanistic Features	223
10.3	LSD Substrates	225
10.4	LSD Function and Dysfunction	229
10.5	LSD Inhibitors	232
10.5.1	Irreversible Small Molecule LSD Inhibitors from MAO Inhibitors	233
10.5.2	Reversible Small Molecule LSD Inhibitors	241
10.5.3	Synthetic Macromolecular LSD Inhibitors	248
10.6	Summary	251
	References	253
<b>11</b>	<b>JmjC-domain-Containing Histone Demethylases</b>	<b>263</b>
	<i>Christoffer Højrup, Oliver D. Coleman, John-Paul Bukowski, Rasmus P. Clausen, and Akane Kawamura</i>	
11.1	Introduction	263
11.1.1	The LSD and JmjC Histone Lysine Demethylases	263
11.1.2	Histone Lysine Methylation and the JmjC-KDMs	265
11.1.3	The JmjC-KDMs in Development and Disease	266
11.2	KDM Inhibitor Development Targeting the JmjC Domain	272
11.2.1	2-Oxoglutarate Cofactor Mimicking Inhibitors	273
11.2.1.1	Emulation of the Chelating $\alpha$ -Keto Acid Moiety in 2OG	273
11.2.1.2	Bioisosteres of the Conserved 2OG C5-Carboxylic Acid-Binding Motif	273
11.2.2	Histone Substrate-Competitive Inhibitors	275
11.2.2.1	Small-Molecule Inhibitors	276
11.2.2.2	Peptide Inhibitors	276
11.2.3	Allosteric Inhibitors	276
11.2.4	Inhibitors Targeting KDM Subfamilies	277
11.2.4.1	KDM4 Subfamily-Targeted Inhibitors	277
11.2.4.2	KDM4/5 Subfamily-Targeted Inhibitors	279
11.2.4.3	KDM5 Subfamily-Targeted Inhibitors	280
11.2.4.4	KDM6 Subfamily-Targeted Inhibitors	281
11.2.4.5	KDM2/7- and KDM3-Targeted Inhibitors	282
11.2.4.6	Generic JmjC-KDM Inhibitors	282
11.2.5	Selectivity and Potency of JmjC-KDM Inhibition in Cells	283

11.3	KDM Inhibitors Targeting the Reader Domains	284
11.3.1	Plant Homeodomain Fingers (PHD Fingers)	284
11.3.2	Tudor Domains	286
11.4	Conclusions and Future Perspectives	286
	Acknowledgments	287
	References	287
<b>12</b>	<b>Histone Acetyltransferases: Targets and Inhibitors</b>	<b>297</b>
	<i>Gianluca Sbardella</i>	
12.1	Introduction	297
12.2	Acetyltransferase Enzymes and Families	298
12.3	The GNAT Superfamily	299
12.3.1	KAT2A/GCN5 and KAT2B/PCAF	301
12.3.2	KAT1/Hat1	303
12.3.3	GCN5L1	304
12.4	KAT3A/CBP and KAT3B/p300 Family	304
12.5	MYST Family	306
12.5.1	KAT5/Tip60	306
12.5.2	KAT6A/MOZ, KAT6B/MORF, and KAT7/HBO1	307
12.5.3	KAT8/MOF	307
12.5.4	SAS2 and SAS3	308
12.5.5	ESA1	308
12.5.6	Other KATs	308
12.6	KATs in Diseases	309
12.7	KAT Modulators	312
12.7.1	Bisubstrate Inhibitors	313
12.7.2	Natural Products and Synthetic Analogues and Derivatives	315
12.7.3	Synthetic Compounds	321
12.7.4	Compounds Targeting Protein–Protein Interaction Domains	328
12.8	Conclusion	333
	References	334
<b>13</b>	<b>Bromodomains: Promising Targets for Drug Discovery</b>	<b>347</b>
	<i>Mehrosh Pervaiz, Pankaj Mishra, and Stefan Günther</i>	
13.1	Introduction	347
13.2	The Human Bromodomain Family	348
13.2.1	Structural Features of the Human BRD Family	348
13.2.1.1	The $K_{ac}$ Binding Site	348
13.2.1.2	Druggability of the Human BRD Family	350
13.2.2	Functions of Bromodomain-containing Proteins	352
13.3	Bromodomains and Diseases	353
13.3.1	The BET Family	354
13.3.2	Non-BET Proteins	356
13.4	Methods for the Identification of Bromodomain Inhibitors	357
13.4.1	High-throughput Screening (HTS)	357
13.4.2	Fragment-based Lead Discovery	359
13.4.3	Structure-based Drug Design	359

13.4.4	Virtual Screening	362
13.4.4.1	Structure-based Virtual Screening	362
13.4.4.2	Ligand-based Virtual Screening	362
13.4.4.3	Pharmacophore Modeling	363
13.4.4.4	Substructure and Similarity Search	363
13.5	Current Bromodomain Inhibitors	364
13.6	Multi-target Inhibitors	365
13.6.1	Dual Kinase–Bromodomain Inhibitors	365
13.6.2	Dual BET/HDAC Inhibitors	369
13.7	Proteolysis Targeting Chimeras (PROTACs)	369
13.8	Conclusions	371
	Acknowledgments	372
	References	372
<b>14</b>	<b>Lysine Reader Proteins</b>	<b>383</b>
	<i>Johannes Bacher, Dina Robaa, Chiara Luise, Wolfgang Sippl, and Manfred Jung</i>	
14.1	Introduction	383
14.2	The Royal Family of Epigenetic Reader Proteins	385
14.2.1	The MBT Domain	385
14.2.2	The PWWP Domain	390
14.2.3	The Tudor Domain	392
14.2.4	The Chromodomain	395
14.3	The PHD Finger Family of Epigenetic Reader Proteins	400
14.4	The WD40 Repeat Domain Family	402
14.5	Conclusion and Outlook	409
	Acknowledgment	409
	References	409
<b>15</b>	<b>DNA-modifying Enzymes</b>	<b>421</b>
	<i>Martin Roatsch, Dina Robaa, Michael Lübbert, Wolfgang Sippl, and Manfred Jung</i>	
15.1	Introduction	421
15.2	DNA Methylation	422
15.3	Further Modifications of Cytosine Bases	424
15.4	DNA Methyltransferases: Substrates and Structural Aspects	426
15.5	Mechanism of Enzymatic DNA Methylation	430
15.6	Physiological Role of DNA Methylation	431
15.7	DNA Methylation in Disease	432
15.8	DNMT Inhibitors	433
15.8.1	Nucleoside-mimicking DNMT Inhibitors	433
15.8.2	Non-nucleosidic DNMT Inhibitors	436
15.9	Therapeutic Applications of DNMT Inhibitors	441
15.10	Conclusion	442
	Acknowledgment	443
	References	443

<b>16</b>	<b>Parasite Epigenetic Targets</b>	<i>457</i>
	<i>Raymond J. Pierce and Jamal Khalife</i>	
16.1	Introduction: The Global Problem of Parasitic Diseases and the Need for New Drugs	<i>457</i>
16.2	Parasite Epigenetic Mechanisms	<i>458</i>
16.2.1	DNA Methylation	<i>459</i>
16.2.2	Histone Posttranslational Modifications	<i>460</i>
16.2.3	Histone-modifying Enzymes in Parasites	<i>462</i>
16.2.4	HMEs Validated as Therapeutic Targets	<i>462</i>
16.2.5	Structure-based Approaches for Defining Therapeutic Targets	<i>464</i>
16.3	Development of Epi-drugs for Parasitic Diseases	<i>465</i>
16.3.1	Repurposing of Existing Epi-drugs	<i>466</i>
16.3.2	Candidates from Phenotypic or High-throughput Screens	<i>467</i>
16.3.3	Structure-based Development of Selective Inhibitors	<i>467</i>
16.4	Conclusions	<i>468</i>
	Acknowledgments	<i>469</i>
	References	<i>469</i>
	<b>Index</b>	<i>477</i>